- A scientific-data oral presentation, two posters and a symposium presentation will highlight the clinical and research advantages of the company’s Afirma molecular test and capabilities -
Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting new data on the company’s Afirma test and capabilities will be presented at ENDO 2023, the annual meeting of The Endocrine Society, which is taking place June 15-18 in Chicago, Ill. Additionally, Veracyte’s medical director of Endocrinology, Joshua Klopper, M.D., will participate in a symposium panel discussion on the advantages of various molecular testing approaches to help personalize and improve care for people with potentially cancerous thyroid nodules.
“The new data we will share at ENDO 2023 demonstrate Veracyte’s ongoing commitment to advancing the science around thyroid nodule management and cancer,” said Dr. Klopper. “They show how we are helping physicians further personalize treatment for their patients with thyroid nodules, while also helping researchers identify additional molecular characteristics of these nodules that could potentially provide clinically actionable prognostic information.”
The following abstracts will be presented at the ENDO 2023 meeting, with all presentations taking place at McCormick Place:
Title: Cytologic and Molecular Assessment of Isthmus Thyroid Nodules
Presenter: Sina Jasim, M.D., M.P.H., Washington University in St. Louis
Session: Poster Session – Late Breaking Poster Abstracts
Date/Time: June 15, 12:30 – 1:30 p.m. CT
Location: ENDO Expo Hall
Title: Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay
Presenter: Priyanka Iyer, M.D., M.D. Anderson Cancer Center
Session: Poster Session - Late Breaking Poster Abstracts
Date/Time: June 17, 1:00 – 2:00 p.m. CT
Location: ENDO Expo Hall
Title: mRNA Expression Based Tumor Behavior Prediction Models in Thyroid Nodules
Presenter: Allan Golding, M.D., Memorial Healthcare System
Session: Oral Presentation - Predicting Thyroid Malignancy: What Tools Do We Have?
Date/Time: June 18, 8:30 – 8:45 a.m. CT
Location: Room W-176
In addition to the new data that will be shared during these presentations, Dr. Klopper will provide his perspective on the role and advantages of Afirma molecular testing during the above-mentioned symposium taking place June 17 from 8:40-9:30 a.m. CT in McCormick Place Room W-181.
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that Veracyte data show how Veracyte helps physicians further personalize treatment for patients with thyroid nodules and also helps researchers identify additional molecular characteristics of thyroid nodules that could potentially provide clinically actionable prognostic information. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 22, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended December 31, 2022. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, the Veracyte logo and Afirma are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.
Veracyte delivers the Afirma Genomic Sequencing Classifier and TERT DNA analysis from its CLIA laboratory. These tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation.